Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Eledon Pharmaceuticals Inc (NASDAQ: ELDN) closed the day trading at $2.71 up 3.83% from the previous closing price of $2.61. In other words, the price has increased by $3.83 from its previous closing price. On the day, 0.88 million shares were traded. ELDN stock price reached its highest trading level at $2.84 during the session, while it also had its lowest trading level at $2.61.
Ratios:
For a better understanding of ELDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.12 and its Current Ratio is at 8.12. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELDN now has a Market Capitalization of 162279680 and an Enterprise Value of 111516928.
Stock Price History:
The Beta on a monthly basis for ELDN is 0.40, which has changed by 0.09716594 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, ELDN has reached a high of $5.54, while it has fallen to a 52-week low of $2.38. The 50-Day Moving Average of the stock is -10.97%, while the 200-Day Moving Average is calculated to be -23.76%.
Shares Statistics:
Over the past 3-months, ELDN traded about 758.04K shares per day on average, while over the past 10 days, ELDN traded about 631570 shares per day. A total of 59.88M shares are outstanding, with a floating share count of 55.83M. Insiders hold about 6.76% of the company’s shares, while institutions hold 64.18% stake in the company. Shares short for ELDN as of 1755216000 were 5461601 with a Short Ratio of 7.20, compared to 1752537600 on 3105017. Therefore, it implies a Short% of Shares Outstanding of 5461601 and a Short% of Float of 10.2.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Eledon Pharmaceuticals Inc (ELDN) in the stock market.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.17 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.49 and -$1.26 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$1.12, with 4.0 analysts recommending between -$0.97 and -$1.31.
